🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Canada / NCT04111718
Active, not recruiting Phase 4

The Impact of Procedural Awareness of Knee Injections for Osteoarthritis on Patient Perceptions of Effectiveness

NCT04111718 · tracked via the Priya Life Science Canada tracker
Sponsor
ArthroBiologix Inc
Phase
Phase 4
Started
2019-10-01
Last updated
2025-09-30

Condition(s) studied

Osteoarthritis, Knee

Investigational drug(s) / intervention(s)

Platelet-rich plasma (PRP) →Viewing of preparation

Platelet-rich plasma (PRP): Autologous platelet-rich plasma which will be derived from blood drawn from the patient.

Viewing of preparation: The patient will receive a description of the preparation process and will view the preparation in the centrifuge.

Study summary

The purpose of this study is to determine whether outcomes for patients receiving intra-articular platelet-rich plasma (PRP) injections for knee osteoarthritis are influenced by observation of the preparatory steps to the procedure. The viewing of the steps involved in the administration of PRP may increase the effectiveness of the treatment in comparison to patients who have not observed the preparatory steps.

Eligibility

Sex
ALL
Min age
50 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Adult men or women ages 50-80 years * Diagnosis of symptomatic osteoarthritis of the knee based on clinical and radiographic criteria * Provision of informed consent Exclusion Criteria: * Patients with inflammatory osteoarthritis * Open wounds or sores over the knee joint * Patients that will likely have problems, in the judgement of the investigators, with maintaining follow-up

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
ArthroBiologix Hamilton Ontario

More ArthroBiologix Inc. trials in Canada

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04111718 on ClinicalTrials.gov ↗ ← All trials in Canada